AN2 Therapeutics Reports Q1 2026 Financial Results with $10M Net Loss and Increased Cash Position

AN2 Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $10.0 million, a decrease from the $10.6 million loss recorded in the same period last year. The company's total operating expenses for the quarter were $10.6 million, down 9% from $11.5 million in the prior year. Research and development expenses decreased by 12% to $6.7 million, primarily due to reduced chemistry manufacturing and controls expenses, while general and administrative expenses remained relatively stable at $3.8 million.

The company’s cash and cash equivalents increased significantly to $53.5 million as of March 31, 2026, compared to $19.9 million at the end of 2025. This increase was bolstered by $37.3 million in net proceeds from a private placement completed in March 2026, which involved the issuance of common stock and pre-funded warrants. AN2 Therapeutics also reported total assets of $87.5 million, up from $62.0 million at the end of the previous fiscal year, reflecting a strong liquidity position to support ongoing operations.

In terms of operational developments, AN2 Therapeutics is advancing its clinical pipeline, with three Phase 2 studies expected to be active in 2026. The company is expanding the development of its oral drug epetraborole into a Phase 2 proof-of-concept study for phlebotomy-dependent polycythemia vera, with plans to initiate the trial in the third quarter of 2026. Additionally, the company is supporting an investigator-initiated trial for epetraborole in M. abscessus lung disease, with patient screening having commenced in March 2026.

The company’s employee headcount has also increased, reflecting its commitment to advancing its research and development efforts. As of March 31, 2026, AN2 Therapeutics had 35,985,599 shares of common stock outstanding, a significant increase from 27,413,171 shares at the end of 2025, indicating a potential increase in investor interest and support for the company’s initiatives.

Looking ahead, AN2 Therapeutics anticipates that its operating expenses will continue to rise as it advances its product candidates through clinical trials and seeks regulatory approvals. The company has indicated that it will require substantial additional capital to fund its ongoing research and development activities, and it plans to finance its operations through public or private equity offerings or debt financings. The management believes that the current cash position will be sufficient to fund operations for at least the next twelve months, but acknowledges the inherent risks and uncertainties associated with drug development and the need for future funding.